PDE5A and pulmonary arterial hypertension: Currently riociguat remains the only oral treatment for patients with CTEPH [14] whereas PAH PDE5-inhibitors are also licensed and often preferred as the first line treatment in patients with advanced age or comorbidities assuming better tolerability [15].